Pd-L1 Expression and Overall Survival Among Patients with Melanoma
Torben Steiniche(Aarhus University), Wei Zhou(Broad Institute), Russell Weiner(Mochida Pharmaceutical (Japan)), Inge Marie Svane(Copenhagen University Hospital), Lars Bastholt(Odense University Hospital), Z. Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Henrik Schmidt(Aarhus University Hospital), Patricia Switten Nielsen(Aarhus University Hospital), Marisa Dolled‐Filhart(Fox Chase Cancer Center), Michael Busch-Sørensen(Center for Clinical & Basic Research), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Allan Vestergaard Danielsen(Aarhus University Hospital)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k